The DOI matches its Crossref record.
Factor V Leiden Mutation and the Risks for Thromboembolic Disease: A Clinical Perspective
Abstract
BACKGROUND: A single point mutation in the gene coding for coagulation factor V results in a form of factor Va that is resistant to degradation by activated protein C and leads to a relative hypercoagulable state. This mutation, factor V Leiden, is found in 4% to 6% of the U.S. population. PURPOSE: To review clinical data on factor V Leiden mutation, with emphasis on prevalence of and risks for thromboembolism and implications for screening and management. DATA SOURCES: A MEDLINE search of the English-language literature published between 1993 and April 1997 and an extensive bibliography review. STUDY SELECTION: Case-control and prospective cohort studies were reviewed if clinical features of thromboembolic disease associated with factor V Leiden mutation or resistance to activated protein C were presented. Original research articles were reviewed if they addressed the identification of the laboratory abnormality of activated protein C or factor V Leiden mutation. Case reports and case series were reviewed when no analytic data were available. DATA EXTRACTION: Review of the identified articles. DATA SYNTHESIS: Factor V Leiden mutation is associated with three- to sixfold increases in risks for primary and recurrent venous thromboembolism, especially in patients without transient risk factors, such as surgery or trauma. Risks for venous thromboembolism in genetically affected persons are substantially higher among patients with coexistent predispositions for thrombosis, such as advanced age, use of oral contraceptives, hyperhomocystinemia, and deficiencies of protein C and protein S. Factor V Leiden mutation does not seem to increase risks for arterial thrombosis. Whether patients with the mutation would benefit from more intense or prolonged anticoagulation is unknown. CONCLUSIONS: The presence of factor V Leiden mutation predisposes patients to venous thromboembolism, but screening for this disorder is of uncertain utility. Decisions about whether to screen for the mutation will depend on the results of clinical trials designed to evaluate the benefit-to-risk ratio of long-term anticoagulation in the secondary prevention of venous thromboembolism in patients with resistance to activated protein C.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Practice Bulletin No. 183: postpartum hemorrhage
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002351 · Cited by 1,406
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Self-citationVascular Actions of Estrogens: Functional Implications
Miller, V. M., & Duckles, S. P. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.08002 · Cited by 593
Vascular-Bed–Specific Hemostasis and Hypercoagulable States
Rosenberg, R. D., & Aird, W. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905203402007 · Cited by 569
Goldhaber, S. Z. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807093390207 · Cited by 428
Metadata
- Authors
- Price, D. T., & Ridker, P. M.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1997-11-15
- Volume
- 127
- Issue
- 10
- Pages
- 895-903
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1964867773
- Cited by
- 274
- References
- 0
- FWCI
- 11.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Factor V Leiden Mutation and the Risks for Thromboembolic Disease: A Clinical Perspective. https://app.cochat.ai/papers/10.7326/0003-4819-127-10-199711150-00007
- The paper
- Price, D. T., & Ridker, P. M. (1997). Factor V Leiden Mutation and the Risks for Thromboembolic Disease: A Clinical Perspective. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-127-10-199711150-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.